- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07951606
Safty and Efficacy of KH658 in Subjects With Diabetic Retinopathy
A Phase II Study to Evaluate the Safty and Efficacy of KH658 Gene Therapy in Participants With Diabetic Retinopathy (DR)
KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for DR could potentially reduce the treatment burden and maintain visual acuity and retinal anatomical stability
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Yan Cheng
- Phone Number: 86-028-81258178
- Email: 025171@cnkh.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Peking Union Medical College Hospital
-
Contact:
- Youxin Chen, MD
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital of Sichuan University
-
Contact:
- Fang Lu, MD
- Phone Number: 028-85422114
- Email: scudag@scu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Are willing and able to sign the informed consent form (ICF);
- Male or female ≥ 18 to 85 years of age with DR secondary to diabetes mellitus Type 1 or Type 2;
- Moderately Severe NPDR or Severe NPDR (DRSS levels 47-53);
- Have a ETDRS BCVA letter score of ≥ 69 (approximately 20/40 Snellen equivalent) in the study eye at Screening;
- Have a ETDRS BCVA letter score of ≥19 (approximately 20/400 Snellen equivalent) in the fellow eye at Screening;
- No active CI-DME
Exclusion Criteria:
- Have any non-DR disease in the study eye judged by the investigator that could impact macular examination or affect central vision or visual acuity improvement (such as macular hemorrhage, central retinal vein occlusion, fovea scar, fibrosis or atrophy etc.);
- Have any vitreous hemorrhage or history of vitreous hemorrhage in the study eye;
- Presence of an implant (excluding intraocular lens), opacification of the refractive medium or miosis that affects fundus examination;
- Have a history of or presence of retinal detachment or choroidal detachment in the study eye.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: KH658 Dose 1
In-office delivers KH658 to the suprachoroidal space |
KH658 Dose 1 suprachoriodal single injection |
|
Experimental: KH658 Dose 2
In-office delivers KH658 to the suprachoroidal space |
KH658 Dose 2 suprachoriodal single injection |
|
Active Comparator: Ranibizumab
Ranibizumab IVT Injection |
Administered by intravitreal injection once a month |
|
No Intervention: Observational Control
Observational Control |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Participants with a ≥2 steps DRSS Improvement From Baseline in Diabetic Retinopthy
Time Frame: At Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants achieving a ≥2 steps improvement on the DRSS from baseline. |
At Week 52
|
|
Proportion of Participants Developing Vision-Threatening Events (VTEs)
Time Frame: At Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants developing VTEs. VTEs include vision-threatening complications (VTCs) and center-involved diabetic macular edema (CI-DME) requiring rescue treatment. |
At Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Participants With Improvement, Maintanance, or Worsening in DRSS Score From Baseline
Time Frame: At Week 24, Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants demonstrating improvement, maintance, or worsening in the DRSS score compared to baseline. |
At Week 24, Week 52
|
|
Time to first occurrence of VTEs
Time Frame: Day 1 to Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the time to first occurrence of VTEs. |
Day 1 to Week 52
|
|
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Through Week 52
|
To evaluate the safty of KH658 ophthalmic injection in patients with DR, assessed by the incidence of AEs and SAEs |
Through Week 52
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of rescue treatments
Time Frame: At Week 24, Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the number of rescue treatments |
At Week 24, Week 52
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Diabetes Mellitus
- Eye Diseases
- Diabetic Angiopathies
- Diabetes Complications
- Retinal Diseases
- Diabetic Retinopathy
- Amino Acids, Peptides, and Proteins
- Proteins
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Ranibizumab
Other Study ID Numbers
- KH658-40301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.